Browse by Audience
Skip to content
Papers of the Week
Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Abstract
Secukinumab, the first IL-17A inhibitor, is widely used to treat immune diseases, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Recently, many studies have reported adverse events associated with secukinumab, including gastrointestinal disorders, infection and infestations, and hypersensitive and nervous system disorders.